Curesponse delivers precision oncology solutions via its cResponse™ test, a combined Genomic-Functional assay designed to predict cancer treatment efficacy. Utilizing a 3-dimensional tissue culture system, the platform preserves tumor architecture and microenvironment to assess patient biopsy responses against chemotherapy, biologics, and immunotherapies. Targeting oncologists and patients, it provides actionable insights for optimizing treatment plans in solid tumors. Additionally, the technology serves pharmaceutical partners for drug development research, aiming to improve clinical outcomes through personalized medicine strategies before treatment initiation with exceptionally high prediction accuracy rates supporting informed decision making.

Curesponse(קיוריספונס בע~מ)

Curesponse(קיוריספונס בע~מ)